{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:19:30Z","timestamp":1720617570746},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11936-017-0510-1","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T07:39:54Z","timestamp":1488958794000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bioresorbable Polymers and Stent Devices"],"prefix":"10.1007","volume":"19","author":[{"given":"Payam","family":"Dehghani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"510_CR1","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873\u201391.","journal-title":"Circulation"},{"key":"510_CR2","doi-asserted-by":"crossref","first-page":"g3859","DOI":"10.1136\/bmj.g3859","volume":"348","author":"S Windecker","year":"2014","unstructured":"Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859.","journal-title":"BMJ"},{"key":"510_CR3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.113.000990","volume":"7","author":"F Otsuka","year":"2014","unstructured":"Otsuka F, Pacheco E, Perkins LE, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330\u201342.","journal-title":"Circ Cardiovasc Interv"},{"key":"510_CR4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","volume":"65","author":"T Palmerini","year":"2015","unstructured":"Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496\u2013507.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR5","volume":"8","author":"J Iqbal","year":"2015","unstructured":"\u2022 Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8, e002230. This study highlights that 1 in 5 patients with best in classs 2nd generation dug eluting stents will, within 5 years of follow up, have a MACE.","journal-title":"Circ Cardiovasc Interv"},{"key":"510_CR6","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2013.07.106","volume":"62","author":"V Farooq","year":"2013","unstructured":"Farooq V, Serruys PW, Zhang Y, et al. Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. J Am Coll Cardiol. 2013;62:2360\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503\u201316.","journal-title":"N Engl J Med"},{"key":"510_CR8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","volume":"367","author":"ME Farkouh","year":"2012","unstructured":"Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375\u201384.","journal-title":"N Engl J Med"},{"key":"510_CR9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","volume":"364","author":"GW Stone","year":"2011","unstructured":"Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226\u201335.","journal-title":"N Engl J Med"},{"key":"510_CR10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400\u20139.","journal-title":"Circulation"},{"key":"510_CR11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.114.012658","volume":"131","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, Yahagi K, Ladich E, et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. Circulation. 2015;131:322\u20134.","journal-title":"Circulation"},{"key":"510_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCINTERVENTIONS.108.844985","volume":"2","author":"B Lagerqvist","year":"2009","unstructured":"Lagerqvist B, Carlsson J, Frobert O, et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2009;2:401\u20138.","journal-title":"Circ Cardiovasc Interv"},{"key":"510_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193\u2013202.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","volume":"109","author":"R Virmani","year":"2004","unstructured":"Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701\u20135.","journal-title":"Circulation"},{"key":"510_CR15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/CIRCULATIONAHA.110.004762","volume":"123","author":"L Raber","year":"2011","unstructured":"Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation. 2011;123:2819\u201328. 6 p following 28.","journal-title":"Circulation"},{"key":"510_CR16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"L Raber","year":"2012","unstructured":"Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA : J Am Med Assoc. 2012;308:777\u201387.","journal-title":"JAMA : J Am Med Assoc"},{"key":"510_CR17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","volume":"379","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393\u2013402.","journal-title":"Lancet"},{"key":"510_CR18","doi-asserted-by":"crossref","first-page":"f6625","DOI":"10.1136\/bmj.f6625","volume":"347","author":"S Bangalore","year":"2013","unstructured":"Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.","journal-title":"BMJ"},{"key":"510_CR19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.058560","volume":"125","author":"L Raber","year":"2012","unstructured":"Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110\u201321.","journal-title":"Circulation"},{"key":"510_CR20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","volume":"33","author":"G Sarno","year":"2012","unstructured":"Sarno G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of \u2018new-generation\u2019 drug-eluting stents: a report from the nationwide Swedish coronary angiography and angioplasty registry (SCAAR). Eur Heart J. 2012;33:606\u201313.","journal-title":"Eur Heart J"},{"key":"510_CR21","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","volume":"380","author":"M Sabate","year":"2012","unstructured":"Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012;380:1482\u201390.","journal-title":"Lancet"},{"key":"510_CR22","doi-asserted-by":"crossref","unstructured":"Van Dyck CJ, Hoymans VY, Bult H, et al. Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model. Catheter Cardiovasc Interv : Off J Soc Cardiac Angiography Interv. 2013;81:E259\u2013E268","DOI":"10.1002\/ccd.24595"},{"key":"510_CR23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","volume":"52","author":"M Joner","year":"2008","unstructured":"Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","volume":"372","author":"S Windecker","year":"2008","unstructured":"Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163\u201373.","journal-title":"Lancet"},{"key":"510_CR25","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/eurheartj\/ehp352","volume":"30","author":"RA Byrne","year":"2009","unstructured":"Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the intracoronary stenting and angiographic results: test efficacy of 3 limus-eluting stents (ISAR-TEST-4) trial. Eur Heart J. 2009;30:2441\u20139.","journal-title":"Eur Heart J"},{"key":"510_CR26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","volume":"381","author":"PC Smits","year":"2013","unstructured":"Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651\u201360.","journal-title":"Lancet"},{"key":"510_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","volume":"62","author":"M Natsuaki","year":"2013","unstructured":"Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR28","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","volume":"384","author":"T Pilgrim","year":"2014","unstructured":"Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111\u201322.","journal-title":"Lancet"},{"key":"510_CR29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.114.013520","volume":"131","author":"C Kaiser","year":"2015","unstructured":"Kaiser C, Galatius S, Jeger R, et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel stent kosten-effektivitats trial-PROspective validation examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation. 2015;131:74\u201381.","journal-title":"Circulation"},{"key":"510_CR30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(14)61794-3","volume":"385","author":"B Raungaard","year":"2015","unstructured":"Raungaard B, Jensen LO, Tilsted HH, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet. 2015;385:1527\u201335.","journal-title":"Lancet"},{"key":"510_CR31","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/eurheartj\/ehu210","volume":"35","author":"S Saito","year":"2014","unstructured":"Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014;35:2021\u201331.","journal-title":"Eur Heart J"},{"key":"510_CR32","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ Cardiovasc Intervent. 2015;8. Data from EVOLVE II trial led to FDA approval of the first bioabsorbable polymer-coated DES in the US with similar 1 year TLR rates to best in class DES.","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372"},{"key":"510_CR33","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214\u201322.","journal-title":"Eur Heart J"},{"key":"510_CR34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441","volume":"8","author":"S Windecker","year":"2015","unstructured":"Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv. 2015;8, e001441.","journal-title":"Circ Cardiovasc Interv"},{"key":"510_CR35","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1016\/j.ijcard.2013.07.263","volume":"168","author":"A Waha de","year":"2013","unstructured":"de Waha A, Stefanini GG, King LA, et al. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. Int J Cardiol. 2013;168:5162\u20136.","journal-title":"Int J Cardiol"},{"key":"510_CR36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCINTERVENTIONS.113.000120","volume":"6","author":"MJ Eppihimer","year":"2013","unstructured":"Eppihimer MJ, Sushkova N, Grimsby JL, et al. Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces. Circ Cardiovasc Interv. 2013;6:370\u20137.","journal-title":"Circ Cardiovasc Interv"},{"key":"510_CR37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","volume":"59","author":"IT Meredith","year":"2012","unstructured":"Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59:1362\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/01.CIR.77.2.361","volume":"77","author":"PW Serruys","year":"1988","unstructured":"Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361\u201371.","journal-title":"Circulation"},{"key":"510_CR39","first-page":"666","volume":"21","author":"S Rathore","year":"2009","unstructured":"Rathore S, Terashima M, Suzuki T. Late-acquired stent malapposition after sirolimus-eluting stent implantation following acute coronary syndrome: angiographic, IVUS, OCT and coronary angioscopic observation. J Invasive Cardiol. 2009;21:666\u20137.","journal-title":"J Invasive Cardiol"},{"key":"510_CR40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/joic.12082","volume":"27","author":"BR Brodie","year":"2014","unstructured":"Brodie BR, Pokharel Y, Garg A, et al. Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16-year single-center experience. J Interv Cardiol. 2014;27:21\u20138.","journal-title":"J Interv Cardiol"},{"key":"510_CR41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004085","volume":"1","author":"K Yamaji","year":"2012","unstructured":"Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 23 years) outcomes of successful balloon angioplasty compared with bare metal coronary stenting. J Am Heart Assoc. 2012;1, e004085.","journal-title":"J Am Heart Assoc"},{"key":"510_CR42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jcin.2013.11.024","volume":"7","author":"JP Lane","year":"2014","unstructured":"Lane JP, Perkins LE, Sheehy AJ, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv. 2014;7:688\u201395.","journal-title":"JACC Cardiovasc Interv"},{"key":"510_CR43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5339\/gcsp.2015.62","volume":"2015","author":"BD Gogas","year":"2015","unstructured":"Gogas BD, King 3rd SB, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan. Glob Cardiol Sci Pract. 2015;2015:62.","journal-title":"Glob Cardiol Sci Pract"},{"key":"510_CR44","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.jcin.2015.06.022","volume":"8","author":"A Tanaka","year":"2015","unstructured":"Tanaka A, Ruparelia N, Kawamoto H, Latib A, Colombo A. Positive vessel remodeling and appearance of pulsatile wall motion at long-term follow-up after bioresorbable scaffold implantation in a chronic total occlusion. JACC Cardiovasc Interv. 2015;8:1635\u20137.","journal-title":"JACC Cardiovasc Interv"},{"key":"510_CR45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4244\/EIJV9I11A217","volume":"9","author":"PW Serruys","year":"2014","unstructured":"Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2014;9:1271\u201384.","journal-title":"EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol"},{"key":"510_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)00447-X","volume":"387","author":"M Haude","year":"2016","unstructured":"Haude M, Ince H, Abizaid A, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016;387:31\u20139.","journal-title":"Lancet"},{"key":"510_CR47","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jacc.2015.11.060","volume":"67","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Ormiston J, van Geuns RJ, et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol. 2016;67:766\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR48","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jacc.2014.09.029","volume":"64","author":"A Karanasos","year":"2014","unstructured":"Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2011.12.008","volume":"221","author":"S Brugaletta","year":"2012","unstructured":"Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221:106\u201312.","journal-title":"Atherosclerosis"},{"key":"510_CR50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.110.971606","volume":"123","author":"Y Onuma","year":"2011","unstructured":"Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779\u201397.","journal-title":"Circulation"},{"key":"510_CR51","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"\u2022\u2022 Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905\u201315. Landmark study of the ABSORB stent, the first bioresorbable vascular scaffold that got FDA approval, which showed, compared to Xience stent, similar target lesion failure rates at 1 year in patients with noncomplex obstructive CAD.","journal-title":"N Engl J Med"},{"key":"510_CR52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","volume":"387","author":"GW Stone","year":"2016","unstructured":"Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the absorb Bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277\u201389.","journal-title":"Lancet"},{"key":"510_CR53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43\u201354.","journal-title":"Lancet"},{"key":"510_CR54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","volume":"65","author":"S Puricel","year":"2015","unstructured":"Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791\u2013801.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR55","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","volume":"10","author":"D Capodanno","year":"2015","unstructured":"Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10:1144\u201353.","journal-title":"EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol"},{"key":"510_CR56","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel S, Cuculi F, Weissner M, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"510_CR57","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4244\/EIJY14M08_08","volume":"10","author":"RP Kraak","year":"2015","unstructured":"Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC single centre real world PCI registry. EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10:1160\u20138.","journal-title":"EuroIntervention : J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol"},{"key":"510_CR58","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","volume":"387","author":"S Cassese","year":"2016","unstructured":"Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387:537\u201344.","journal-title":"Lancet"},{"key":"510_CR59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","volume":"9","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9:12\u201324.","journal-title":"JACC Cardiovasc Interv"},{"key":"510_CR60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ccd.26172","volume":"86","author":"DG Rizik","year":"2015","unstructured":"Rizik DG, Hermiller JB, Kereiakes DJ. The ABSORB Bioresorbable vascular scaffold: a novel, fully resorbable drug-eluting stent: current concepts and overview of clinical evidence. Catheter Cardiovasc Interv : Off J Soc Cardiac Angiography Interv. 2015;86:664\u201377.","journal-title":"Catheter Cardiovasc Interv : Off J Soc Cardiac Angiography Interv"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-017-0510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-017-0510-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-017-0510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T12:37:34Z","timestamp":1568896654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-017-0510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1007\/s11936-017-0510-1","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"article-number":"12"}}